POLICY BRIEFINGS
Hart Health Strategies provides a comprehensive policy briefing on a weekly basis. This in-depth health policy briefing is sent out at the beginning of each week. The health policy briefing recaps the previous week and previews the week ahead. It alerts clients to upcoming congressional hearings, newly introduced bills, regulatory announcements, and implementation activity related to the Patient Protection and Affordable Care Act (PPACA) and other health laws.
THIS WEEK'S BRIEFING - JUNE 10, 2019
- PAHPA Passes House, Sent to President Trump
- Ag-FDA Spending Bill Advances Out of Committee
- CBO Works to Score Surprise Insurance Gap Legislation
- Senators Release List of Under-Performing Nursing Homes
- House Dems Request Info on Direct Enrollment
- House to Begin Consideration of $1 Trillion in Spending Bills this Week
- Finance Drug Pricing Proposal Expected June 19
- Trump Administration Personnel Updates
- Upcoming Congressional Hearings and Markups
- Recently Introduced Health Legislation
- Recently Introduced Health Legislation Cont.
PAHPA Passes House, Sent to President Trump
The House of Representatives passed S. 1379, the Pandemic and All-Hazards Preparedness and Advancing Innovation Act under suspension of the rules by voice vote last week. The legislation would reauthorize programs related to emergency preparedness and public health response efforts. Most of these programs expired last September but were funded under fiscal year (FY) 2019 appropriations legislation. The bill will now be sent to the President’s desk, where it is expected to be signed into law.
Ag-FDA Spending Bill Advances Out of Committee
The House Appropriations Committee advanced its Agriculture-Rural Development-Food and Drug Administration (FDA) fiscal year (FY) 2020 spending bill along party lines last week. It includes $24.3 billion in discretionary funding, an increase of $1 billion over current levels. The FDA would receive a total of $3.3 billion, $184 million above FY 2019. The panel adopted an amendment from Rep. Robert Aderholt (R-Ala.) that would ban the advancement of research and technology related to the modification of human embryos or gene editing. The same rider was placed on the FY 2019 spending bill but had been dropped in subcommittee last month. The committee’s report language expresses support for stronger regulation of cosmetics and dietary supplements. The panel requests a briefing on the staffing and budget resources FDA would need to improve its oversight of cosmetics, and whether user fees would be helpful in supporting the agency’s work in this space. Appropriators also request a briefing with the agency on the issue of office-use compounding.
June 10, 2019: | Page 1 Page 2 Page 3 Page 4
SERVICES
- Strategy & Planning
- Information & Counsel
- Washington Presence & Influence
- Materials Development
- Grassroots Advocacy
- Partnership & Coalition Building
- Communications
BRIEFING ARCHIVE
- 2023
- - September 2023
- 9/25/23 VIEW | PRINTABLE PDF
- 9/18/23 VIEW | PRINTABLE PDF
- 9/11/23 VIEW | PRINTABLE PDF
- 9/5/23 VIEW | PRINTABLE PDF
- + August 2023
- + July 2023
- + June 2023
- + May 2023
- + April 2023
- + March 2023
- + February 2023
- + January 2023